PWA
CYTK icon

Phoenix Wealth Advisors’s Cytokinetics CYTK Stock Holding History

Phoenix Wealth Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,274
Closed -$242K – 106
2022
Q4 		$242K Buy
+5,274
New +$227K 0.15% 94

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Phoenix Wealth Advisors's CYTK Position: Q1 2023 in Review

Phoenix Wealth Advisors sold out of Cytokinetics (CYTK) in Q1 2023, closing a stake of 5,274 shares — an estimated $242K sold.

Phoenix Wealth Advisors first reported a position in CYTK in Q4 2022 and held it in 1 quarter. The position peaked at $242K in Q4 2022. 262 funds tracked by Wall St. Rank hold CYTK as of Q1 2023.

  • Phoenix Wealth Advisors reported no remaining Cytokinetics position as of Q1 2023 after selling out during the quarter.
  • Phoenix Wealth Advisors sold 5,274 Cytokinetics shares in Q1 2023, an estimated $242K.
  • Phoenix Wealth Advisors first reported a position in Cytokinetics in Q4 2022 and held it in 1 quarter.
  • Phoenix Wealth Advisors's Cytokinetics position peaked at $242K in Q4 2022.
  • 262 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2023.

Based on Phoenix Wealth Advisors's 13F filing for Q1 2023, filed 5 May 2023.